UNSPSC 51131660: Danaparoid

This classification denotes a low molecular weight heparin with the molecular formula C14H18NO17S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BI6GY4U9CW, more generally known as danaparoid. European Medicines Agency schedules Danaparoid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13531MIG. As of Q4 2014, DANAPAROID remains the US FDA Preferred Term for this commodity. SMILES: NONE.

UNSPSC 51131660 Danaparoid is a Commodity code with minimal recent state and local procurement activity reflecting its narrow pharmaceutical scope. The single recent opportunity tagged to this code—Sourcewell's RFP #061626 for Law Enforcement Equipment posted May 12, 2026, with response due June 16, 2026—appears misclassified and does not align with the code's pharmaceutical anticoagulant specification. The mismatch suggests that state and local procurement offices rarely solicit danaparoid through formal competitive notice, or when they do, tagging accuracy is unreliable. Danaparoid is a specialized injectable anticoagulant typically procured through established pharmaceutical supply contracts, hospital group purchasing organizations, or standing healthcare vendor agreements rather than open competitive solicitations, making it largely invisible in the state and local RFP, RFQ, IFB, and ITB market that forms the basis for this analysis.

No relevant recent opportunities under this code are identifiable from the available source material. Procurement professionals should expect danaparoid demand to flow through existing healthcare system contracts, cooperative pharmaceutical purchasing vehicles, and direct vendor relationships rather than competitive state and local notices. Activity in this code, if it exists, would be limited to specialized healthcare facilities and does not represent an active pursuit opportunity based on current public solicitation patterns.